HCA Healthcare (HCA) Stock Forecast & Price Target

$326.15 -6.85 (-2.06%)

(As of 12:45 PM ET)

HCA Healthcare - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 19 Analyst Ratings

Sell
0

Hold
5

Buy
14

Based on 19 Wall Street analysts who have issued ratings for HCA Healthcare in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 5 have given a hold rating, 12 have given a buy rating, and 2 have given a strong buy rating for HCA.

Consensus Price Target

$385.00
18.04% Upside

According to the 19 analysts' twelve-month price targets for HCA Healthcare, the average price target is $385.00. The highest price target for HCA is $440.00, while the lowest price target for HCA is $271.00. The average price target represents a forecasted upside of 18.04% from the current price of $326.15.

Get the Latest News and Ratings for HCA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for HCA Healthcare and its competitors.

HCA Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	2 Strong Buy rating(s)	3 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	14 Buy rating(s)	14 Buy rating(s)	14 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$385.00	$367.15	$356.17	$296.59
Forecasted Upside	18.04% Upside	-10.05% Downside	-8.39% Downside	17.22% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)

The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…

Claim your FREE 2024 Gold Guide

HCA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HCA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

HCA Healthcare Stock vs. The Competition

Type	HCA Healthcare	Medical Companies	S&P 500
Consensus Rating Score	2.84	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	15.62% Upside	26,931.47% Upside	9.83% Upside
News Sentiment Rating	Positive News See Recent HCA News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/8/2024	Barclays 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$396.00 ➝ $392.00	+11.12%
11/6/2024	Wells Fargo & Company 3 of 5 stars		Boost Target	Equal Weight ➝ Equal Weight	$395.00 ➝ $400.00	+14.58%
10/28/2024	TD Cowen 4 of 5 stars		Lower Target	Buy ➝ Buy	$450.00 ➝ $440.00	+22.05%
10/28/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$390.00 ➝ $400.00	+10.22%
10/28/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Gillmor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$475.00 ➝ $420.00	+15.73%
10/1/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$392.00 ➝ $392.00	-3.18%
Get the Latest News and Ratings for HCA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for HCA Healthcare and its competitors with MarketBeat's FREE daily newsletter.
9/3/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Equal Weight	$427.00	+7.94%
8/29/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Lake Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/23/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$378.00 ➝ $405.00	+5.09%
8/19/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$390.00 ➝ $430.00	+15.30%
8/14/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$405.00 ➝ $438.00	+18.74%
7/24/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$367.00 ➝ $396.00	+16.32%
6/28/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$359.00 ➝ $375.00	+14.85%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/30/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$327.00 ➝ $332.00	-0.86%
5/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$396.00	+21.88%
1/31/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$300.00 ➝ $330.00	+9.45%
1/4/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$277.00 ➝ $301.00	+9.85%
12/11/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$271.00	+5.23%
11/10/2023	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$280.00	+20.26%
10/25/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$325.00 ➝ $275.00	+21.19%
10/25/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$324.00 ➝ $279.00	+22.87%
7/28/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$311.00 ➝ $316.00	+14.31%
6/28/2023	1-800-FLOWERS.COM Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
6/28/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/10/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$285.00 ➝ $310.00	+13.12%
4/24/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$325.00 ➝ $350.00	+23.24%
4/24/2023	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$285.00 ➝ $320.00	+13.79%
4/24/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$294.00 ➝ $323.00	+14.86%
1/30/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$238.00 ➝ $292.00	+14.61%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:05 PM ET.

HCA Forecast - Frequently Asked Questions

: According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for HCA Healthcare is $385.00, with a high forecast of $440.00 and a low forecast of $271.00.
: 19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HCA Healthcare in the last twelve months. There are currently 5 hold ratings, 12 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HCA shares.
: According to analysts, HCA Healthcare's stock has a predicted upside of 18.04% based on their 12-month stock forecasts.
: Over the previous 90 days, HCA Healthcare's stock had 2 upgrades by analysts.
: HCA Healthcare has been rated by research analysts at Barclays, Cantor Fitzgerald, KeyCorp, Morgan Stanley, Oppenheimer, Royal Bank of Canada, TD Cowen, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like HCA Healthcare more than other "medical" companies. The consensus rating score for HCA Healthcare is 2.84 while the average consensus rating score for "medical" companies is 2.80. Learn more on how HCA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

When it comes to NVDA… “acceleration cycles” are the key (Ad)

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

This page (NYSE:HCA) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HCA Healthcare (HCA) Stock Forecast & Price Target